Priaxon AG


    • Company type:
      • Research & Development
    • Year founded:
    • 2008
    • Employees (at the site):
    • 16
    • Turnover range:
    • <5m EUR
    • Products/services:
    • Priaxon is an emerging pharmaceutical company building a pipeline of novel drug candidates in different therapeutic fields, but mainly focusing on protein-protein interactions in oncology and other diseases. The goal is to discover and develop candidates for validated but hard-to-drug targets using two orthogonal drug discovery platforms. In January 2009 a collaboration agreement for the development of mdm2/p53-inhibitors with Boehringer Ingelheim was signed.
      We open up a new dimension in drug discovery by a unique combination of proprietary chemoinformatic tools with innovative synthetic chemistries. As a result Priaxon rationalizes and accelerates the whole drug discovery process.

    • Core competencies:
    • Priaxon's key expertise lies in the unification of highly innovative preparative strategies with equally ground-breaking novel chemoinformatic methods. By the combination of several hundreds of validated multicomponent reactions (MCRs) with classical organic chemistry the largest molecular space of drug-like compounds (>1billion) is accessible. To navigate this space new powerful molecular descriptors and superior filter algorithms have been developed. As a result of this integrated approach combining innovative preparative strategies with outstanding chemoinformatics usually new active chemical entities can be identified within few months. This enables a fast proof of concept and leads to a very time- and cost-efficient drug discovery process. The technology itself is very general and thus not limited to any special field of indication.

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Bioinformatics and cheminformatics
      • Biotechnology: Biotechnological reagents
      • Chemical Industry: Pharmaceutical preparations
    • Industries NACE:
      • 21.10: Manufacture of basic pharmaceutical products
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Jürgen Kolb (Mr.)
      - Management

      Dr. Christoph Burdack (Mr.)
      - Management

      Günther Ross (Mr.)
      - Research & development